Temozolomide - Merck & Co
Alternative Names: CCRG-81045; MB-39831; MK-7365; NSC-362856; RP-46161; SCH-52365; Temcad; Temodal; Temodar; TemomedacLatest Information Update: 15 Jul 2024
At a glance
- Originator Cancer Research UK
- Developer AbbVie; H. Lee Moffitt Cancer Center and Research Institute; MediciNova; Merck & Co; Schering-Plough; Stanford University; University of Texas M. D. Anderson Cancer Center
- Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Small molecules; Triazenes
- Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaplastic astrocytoma; Glioma; Malignant melanoma
- Registered Ewing's sarcoma
- Phase II Acute myeloid leukaemia; Breast cancer; Glioblastoma
- No development reported Brain metastases; Gliosarcoma; Myelodysplastic syndromes; Non-small cell lung cancer; Small cell lung cancer
- Discontinued Non-Hodgkin's lymphoma; Prostate cancer; Sarcoma
Most Recent Events
- 31 May 2024 Efficacy data from a phase I/II trial in Glioblastoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 Jun 2023 H. Lee Moffitt Cancer Center and Research Institute in collaboration with Merck completes a phase I trial in Gliosarcoma and Glioblastoma (Newly diagnosed, Combination therapy) in USA (PO) (NCT03426891)
- 21 Oct 2022 Phase-II clinical trials in Glioblastoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT05463848)